Blocking HIF1α Activity Eliminates Hematological Cancer Stem Cells  by Lam, Ben S. & Adams, Gregor B.
Cell Stem Cell
Previewsa model wherein the fat body senses die-
tary factors (e.g., amino acids) via Slif/
TOR signaling, and secretes a systemic
signal(s) to both mNSCs and glia that
increases circulating and local ILP levels,
respectively. Systemic ILPs promote
organismal growth (and adult GSC and
ISC activity), while local glial ILPs act
directly on neuroblasts to promote
reactivation.
Why are neuroblasts unresponsive to
systemic ILPs (e.g., in contrast to adult
GSCs and ISCs)? Gould and colleagues
speculate that the CNS neuroblasts might
be physically isolated from systemic ILPs
by the blood brain barrier, thus requiring
a local source of ILPs (Sousa-Nunes
et al., 2011). It is conceivable, however,
that other stem cells might also respond
to local ILPs, considering that multiple
tissues express functionally redundant
ILPs. In this scenario, differences in ILP
source between stem cell populations
might simply reflect a varying requirement
for high local concentrations of ILPs ac-
cording to insulin signaling response
thresholds.
These findings represent the ‘‘tip of the
iceberg’’ for what is likely a complex and
sophisticated physiological network
impinging on stem cells in response to
dietary fluctuations (Figure 1). The fat
body is emerging as a central player in354 Cell Stem Cell 8, April 8, 2011 ª2011 Elsthis network, in remarkable parallel to
the mammalian adipose tissue, which
has major endocrine roles. Given that
distinct populations of ILP-producing
cells (i.e., glia and mNSCs) are modulated
by diet-dependent, fat body-derived
systemic signals, it is possible that
different factors might target each popu-
lation. Such systemic signals might also
control additional local signals or act
directly on stem cells in different tissues.
Multiple fat body signals—possibly
a combination of signaling lipids and/or
peptide hormones, as for the mammalian
adipose tissue—would allow the fat body
to coordinate rapid stem cell-specific
responses to different types of dietary
fluctuations.
Finally, the question of how diet and
other physiology-altering factors (such
as aging, stress, injury, or infection)
impact stem cell populations is highly
relevant to our understanding of stem
cell biology in general (reviewed in Drum-
mond-Barbosa, 2008). As recent studies
exemplify (Chell and Brand, 2010;
Sousa-Nunes et al., 2011; Hsu and Drum-
mond-Barbosa, 2009), the answer to this
multilayered question lies not only in iden-
tifying the organs/tissues/cells and
respective systemic factors involved in
modulating various stem cell populations,
but also in elucidating how these humoralevier Inc.signals are integrated with each other and
with local and intrinsic factors to control
stem cell behavior.REFERENCES
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Selective targeting of cancer stem cells (CSCs) has the potential to prevent cancer relapse. Wang et al. (2011)
report that hypoxia-inducible factor 1a (HIF1a) represses Notch signaling to maintain CSC subsets from
lymphoma, and that blocking HIF1a activity eliminates lymphoma and human acute myeloid leukemia
(AML) CSCs.The cancer stem cell hypothesis posits
that CSCs are a subpopulation present
within a tumor that undergoes self-re-newal to drive tumorigenesis when serially
transplanted into recipients and, in doing
so, differentiate into the heterogeneouscell types that characterize the tumor of
origin (Wicha et al., 2006). The first evi-
dence supporting the concept of CSCs
Figure 1. Selective Targeting of Cancer Stem Cells by Echinomycin
Under normoxic conditions, HIF1a is active in cancer stem cells (CSCs), but
not in hematopoietic stem cells (HSCs). Through selective targeting of
HIF1a, echinomycin efficiently eliminates CSCs while sparing the normal
HSCs. As a result, CSCmaintenance is disrupted, and there is no tumor forma-
tion when these cells are transplanted into immunodeficient mouse hosts.
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Previewswas reported by Lapidot
et al. (1994), who identified
a small population of acute
myeloid leukemia (AML)-initi-
ating cells on the basis of their
ability to give rise to leukemia
in severe combined immuno-
deficient (SCID)mice (Lapidot




displayed the cell surface
phenotype CD34+CD38 and
were able to produce large
numbers of colony-formingprogenitors. Interestingly, the CD34+
CD38+ and CD34 subpopulations did
not have these properties, suggesting a
hierarchical relationship among leukemic
cells in human AML. Since CSCs were
identified in leukemia, numerous studies
have identified signaling pathways
involved in the maintenance of CSCs in
solid tumors as well, including Bmi-1,
Wnt, Notch, and Hedgehog signaling
pathways (Lessard and Sauvageau,
2003; Beachy et al., 2004; Shih and
Wang, 2007; Zhao et al., 2009). Given
that these pathways in many cases are
also key inmaintaining homeostatic tissue
repair and regeneration, it is not clear that
they can be targeted to eliminate CSCs
without adverse effects on normal stem
cell function. Identifying effective cancer
treatment strategies that selectively elimi-
nate CSCs is therefore an important
therapeutic goal. In this issue of Cell
Stem Cell, Wang et al. (2011) report that
echinomycin, a hypoxia-inducible factor
1a (HIF1a) inhibitor, selectively eradicates
CSCs inmousemodels for lymphoma and
human AML.
Hypoxia occurs in tumors due to rapid
cell proliferation and aberrant blood
vessel formation. In response to hypoxic
stress, the expression of HIFs, which are
heterodimeric transcription factors con-
sisting of an a and b subunit, is regulated
accordingly to mediate cellular and sys-
temic adaptation (Keith and Simon,
2007). Unlike HIFb subunits, which are
constitutively active, HIFa subunits are
tightly regulated, depending on the level
of oxygenation. Under normoxic condi-
tions, HIFa subunits are rapidly ubiquiti-
nated through interaction with the von
Hippel-Lindau tumor suppressor protein
(VHL) and degraded in the proteasome(Semenza, 2003). Unexpectedly, Wang
et al. (2011) found that a subset of
c-Kit+Sca-1+ lymphoma CSCs maintain
high levels of HIF1a protein and downre-
gulate VHL under normoxic conditions.
In colony-forming assays, they found
that HIF1a signaling was required to
maintain the c-Kit+Sca-1+ subset. As a
result, the authors found that echinomy-
cin, a peptide antibiotic that intercalates
into DNA to block the binding of HIF1a,
effectively inhibited self-renewal using
colony-forming unit (cfu) formation as
a readout. More importantly, Wang et al.
(2011) demonstrated that syngeneic
mice injected with lymphoma cells
and receiving echinomycin treatments
showed enhanced survival while un-
treated mice succumbed after 2 months.
To determine the specificity of echinomy-
cin on targeting CSCs, the authors tested
the drug sensitivity of normal hematopoi-
etic c-Kit+Sca-1+ cells and compared
them to lymphoma c-Kit+Sca-1+ cells.
Notably, the lymphoma c-Kit+Sca-1+ cells
were significantly more sensitive to
echinomycin than normal hematopoietic
c-Kit+Sca-1+ cells (Figure 1), suggesting
that therapeutic agents interfering with
HIF1a signaling may spare normal hema-
topoietic function.
Investigating the underlying signaling
mechanisms involved, Wang et al. (2011)
noted an increase in the expression of
the Notch target gene Hes1 in the
lymphoma c-Kit+Sca-1+ cells, and that
the expression could be reduced by
knocking down HIF1a. To substantiate
the role of Notch signaling in the self-
renewal of CSCs, the authors utilized a
dominant-negative regulator of Notch
signaling and showed a significant reduc-
tion in the percentage of c-Kit+Sca-1+Cell Stem Cell 8, April 8cells and cfu activity. When
these cells were transplanted
into syngeneic mice, the
development of lymphoma
was delayed. Furthermore,
the authors discovered that
HIF1a could reverse the
autoregulation of Hes1 in a
dose-dependent manner,
providing evidence that Notch
signaling is involved in the self-
renewal of CSCs and that
HIF1a enhances Notch-
induced Hes1 expression by
blocking a negative-feedback
autoregulation of Hes1.Based on their results in a mouse
model of lymphoma, Wang et al. (2011)
explored the therapeutic potential of
HIF inhibitors for human AML. Similar
to their findings in the lymphoma
CSCs, they observed an increase in
HIF1a expression in CD34+CD38 AML
leukemic stem cells (LSCs) and a reduc-
tion in cfu when the LSCs were trans-
duced with HIF1a shRNA to knock
down HIF1a. HIF1a knockdown also
resulted in a significant reduction in
the sensitivity of cfu to echinomycin,
suggesting that echinomycin also tar-
geted HIF1a in human AML. Intrigued by
the possibility that echinomycin could
potentially have a therapeutic effect on
AML, the authors utilized a xenogeneic
model of human AML and discovered
that short-term echinomycin treatment
prevented serial transplantation of
AML. These results suggest that echino-
mycin may also selectively target AML-
LSCs.
The findings by Wang et al. (2011)
reinforce the notion that functional
conservation of Notch signaling is re-
quired for maintenance of both CSCs
and normal adult stem cells and suggest
that a HIF1a/Notch regulatory loop may
be specifically required to regulate CSC
self-renewal. Previous work has sug-
gested an involvement of HIF signaling
in other types of cancers, but here the
authors provided additional insight
into the potential use of HIF inhibitors
to selectively target CSCs while mini-
mizing any detrimental effects on nor-
mal hematopoietic progenitor cells.
Further progress in identifying pharmaco-
logical agents that selectively target
CSCs is pivotal for advancing cancer
therapeutics., 2011 ª2011 Elsevier Inc. 355
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